This study addresses the FY21 MRP Focus area: Develop prediction and surveillance tools for distinguishing patients at risk for recurrence and/or metastasis. In line with the FY21 MRP Challenge Statement this research will develop prognostic liquid biomarkers to stop melanoma recurrence and progression. The liquid biopsy-based prediction model will identify stage IIB/IIC melanoma patients at high-risk of recurrence to tailor treatments to ensure the best patient outcomes. At the same time, patients who are cured by surgery alone will be spared unnecessary treatments that can cause significant and persisting morbidities.
|Effective start/end date||1/09/22 → 31/08/25|